{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:55:11Z","timestamp":1788897311096,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015613","name":"Centre Hospitalier Universitaire de Lille","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015613","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>Malignant transformation in patients with monoclonal gammopathy of undetermined significance treated with teriparatide was evaluated. Among 29 patients, only two progressed to hematologic malignancy (one multiple myeloma, one Waldenstr\u00f6m\u2019s macroglobulinemia). These findings are reassuring and suggest that TPT may remain an option for selected patients with severe osteoporosis and MGUS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Osteoporosis is a highly prevalent bone disease with limited therapeutic options, particularly in multimorbid patients. Monoclonal gammopathy of undetermined significance (MGUS), a frequent finding in osteoporosis and a recognized fracture risk factor, often leads to contraindication of teriparatide (TPT), further restricting treatment choices. This study aimed to assess hematologic malignant transformation in osteoporotic patients with MGUS treated with TPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective bicenter observational study was conducted at Lille and Angers University Hospitals (2016\u20132022). Patients with osteoporosis and confirmed MGUS at TPT initiation were included. Demographic, hematologic, bone, and treatment parameters were collected. In parallel, hematologic malignancies reported with TPT were reviewed from the French national pharmacovigilance database (PVDB) over the same period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-nine patients (69% women; mean age 72.6\u2009\u00b1\u200912.6\u00a0years) were included. Most had major comorbidities (89.7% with Charlson Comorbidity Index\u2009\u2265\u20093). MGUS was IgG-type in 55.2% and IgM-type in 41.4%. The mean follow-up from TPT initiation was 60.2\u2009\u00b1\u200930.7\u00a0months (median 54.0; 95% CI 49.0\u201371.4). Two patients developed hematologic malignancy: one multiple myeloma (MM) 7\u00a0years after TPT and one Waldenstr\u00f6m\u2019s macroglobulinemia 21\u00a0months after initiation, both with intermediate-risk MGUS. TPT was well tolerated with premature discontinuation in 17.2% of cases. Of the two hematologic malignancies identified in the PVDB, only one (MM) occurred in a patient with pre-existing MGUS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Malignant progression was rare, providing reassuring evidence regarding hematologic safety. TPT may be considered in selected patients with severe osteoporosis and MGUS, provided careful hematologic monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01693-x","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T11:42:44Z","timestamp":1774784564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Malignant transformation in patients with monoclonal gammopathy of undetermined significance treated with teriparatide for osteoporosis: a bicenter retrospective study and analysis of the French national pharmacovigilance database"],"prefix":"10.1007","volume":"21","author":[{"given":"R.","family":"Cassez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bouvard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Theis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Potey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Paccou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2630-8666","authenticated-orcid":false,"given":"C.","family":"Philippoteaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"1693_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.6003","author":"SN Morin","year":"2025","unstructured":"Morin SN, Leslie WD, Schousboe JT (2025) Osteoporosis: a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.6003","journal-title":"JAMA"},{"key":"1693_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82. https:\/\/doi.org\/10.1007\/s11657-020-00871-9","journal-title":"Arch Osteoporos"},{"issue":"3","key":"1693_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","volume":"42","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H et al (2008) A reference standard for the description of osteoporosis. Bone 42(3):467\u201375. https:\/\/doi.org\/10.1016\/j.bone.2007.11.001","journal-title":"Bone"},{"key":"1693_CR4","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1016\/S2666-7568(21)00172-0","volume":"2","author":"GBD 2019 Fracture Collaborators","year":"2021","unstructured":"GBD 2019 Fracture Collaborators (2021) Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev 2:e580-92. https:\/\/doi.org\/10.1016\/S2666-7568(21)00172-0","journal-title":"Lancet Healthy Longev"},{"issue":"5","key":"1693_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jbspin.2018.02.009","volume":"85","author":"K Briot","year":"2018","unstructured":"Briot K, Roux C, Thomas T et al (2018) 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine 85(5):519\u201330. https:\/\/doi.org\/10.1016\/j.jbspin.2018.02.009","journal-title":"Joint Bone Spine"},{"key":"1693_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"key":"1693_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/M22-1034","volume":"176","author":"A Qaseem","year":"2023","unstructured":"Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I et al (2023) Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med 176:224\u201338. https:\/\/doi.org\/10.7326\/M22-1034","journal-title":"Ann Intern Med"},{"key":"1693_CR8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u201341. https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"key":"1693_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.9","journal-title":"J Bone Miner Res"},{"key":"1693_CR10","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028\u201339. https:\/\/doi.org\/10.1056\/NEJMoa071408","journal-title":"N Engl J Med"},{"key":"1693_CR11","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362\u20139. https:\/\/doi.org\/10.1056\/NEJMoa054494","journal-title":"N Engl J Med"},{"issue":"12","key":"1693_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538-548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"1693_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564\u20139. https:\/\/doi.org\/10.1056\/NEJMoa01133202","journal-title":"N Engl J Med"},{"issue":"1","key":"1693_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/ejh.13633","volume":"107","author":"S R\u00f6gnvaldsson","year":"2021","unstructured":"R\u00f6gnvaldsson S, Aspelund T, Thorsteinsd\u00f3ttir S et al (2021) Untangling fracture risk in monoclonal gammopathy of undetermined significance: a population-based cohort study. Eur J Haematol 107(1):137\u201344. https:\/\/doi.org\/10.1111\/ejh.13633","journal-title":"Eur J Haematol"},{"issue":"1","key":"1693_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00774-017-0817-8","volume":"36","author":"N Veronese","year":"2018","unstructured":"Veronese N, Luchini C, Solmi M et al (2018) Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis. J Bone Miner Metab 36(1):128\u201332. https:\/\/doi.org\/10.1007\/s00774-017-0817-8","journal-title":"J Bone Miner Metab"},{"key":"1693_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00198-018-4787-z","volume":"30","author":"EM Stein","year":"2019","unstructured":"Stein EM, Dash A, Bucovsky M et al (2019) Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance. Osteoporos Int 30:629\u201335. https:\/\/doi.org\/10.1007\/s00198-018-4787-z","journal-title":"Osteoporos Int"},{"key":"1693_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1359\/jbmr.070413","volume":"22","author":"P Chen","year":"2007","unstructured":"Chen P, Miller PD, Recker R et al (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173\u201380. https:\/\/doi.org\/10.1359\/jbmr.070413","journal-title":"J Bone Miner Res"},{"key":"1693_CR18","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1210\/jc.2003-032066","volume":"89","author":"EC Buxton","year":"2004","unstructured":"Buxton EC, Yao W, Lane NE (2004) Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 89:3332\u20133336. https:\/\/doi.org\/10.1210\/jc.2003-032066","journal-title":"J Clin Endocrinol Metab"},{"key":"1693_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","volume":"8","author":"B Langdahl","year":"2016","unstructured":"Langdahl B, Ferrari S, Dempster DW (2016) Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 8:225\u2013235. https:\/\/doi.org\/10.1177\/1759720X16670154","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1693_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3275\/7925","volume":"34","author":"BC Silva","year":"2011","unstructured":"Silva BC, Costa AG, Cusano NE et al (2011) Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest 34:801\u2013810. https:\/\/doi.org\/10.3275\/7925","journal-title":"J Endocrinol Invest"},{"key":"1693_CR21","first-page":"9932","volume":"13","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Guo M, Gu C et al (2021) The role of Wnt\/\u03b2-catenin signaling pathway in the pathogenesis and treatment of multiple myeloma (review). Am J Transl Res 13:9932\u20139949","journal-title":"Am J Transl Res"},{"key":"1693_CR22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.ajpath.2015.11.003","volume":"186","author":"A Lu","year":"2016","unstructured":"Lu A, Pallero MA, Lei W et al (2016) Inhibition of transforming growth factor-\u03b2 activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma. Am J Pathol 186:678\u2013690. https:\/\/doi.org\/10.1016\/j.ajpath.2015.11.003","journal-title":"Am J Pathol"},{"key":"1693_CR23","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1172\/JCI118947","volume":"98","author":"TA Guise","year":"1996","unstructured":"Guise TA, Yin JJ, Taylor SD et al (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544\u20139. https:\/\/doi.org\/10.1172\/JCI118947","journal-title":"J Clin Invest"},{"key":"1693_CR24","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5435\/JAAOS-D-22-01094","volume":"31","author":"CL McDonald","year":"2023","unstructured":"McDonald CL, Johnson K, Alsoof D et al (2023) Treatment of osteoporosis with anabolic agents and the risk of primary bone cancers: a study of 44,728 patients treated with teriparatide and abaloparatide. J Am Acad Orthop Surg 31:520\u20138. https:\/\/doi.org\/10.5435\/JAAOS-D-22-01094","journal-title":"J Am Acad Orthop Surg"},{"key":"1693_CR25","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani N, Rizzoli V, Roodman GD (2006) Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108:3992\u20136. https:\/\/doi.org\/10.1182\/blood-2006-05-026112","journal-title":"Blood"},{"key":"1693_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bone.2015.02.021","volume":"75","author":"MR Reagan","year":"2015","unstructured":"Reagan MR, Liaw L, Rosen CJ et al (2015) Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone 75:161\u20139. https:\/\/doi.org\/10.1016\/j.bone.2015.02.021","journal-title":"Bone"},{"key":"1693_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10665","volume":"6","author":"JH Krege","year":"2022","unstructured":"Krege JH, Gilsenan AW, Komacko JL et al (2022) Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. JBMR Plus 6:e10665. https:\/\/doi.org\/10.1002\/jbm4.10665","journal-title":"JBMR Plus"},{"key":"1693_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312\u201321. https:\/\/doi.org\/10.1080\/01926230252929882","journal-title":"Toxicol Pathol"},{"key":"1693_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116394","volume":"160","author":"N Kellier-Steele","year":"2022","unstructured":"Kellier-Steele N, Casso D, Anderson A et al (2022) Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes. Bone 160:116394. https:\/\/doi.org\/10.1016\/j.bone.2022.116394","journal-title":"Bone"},{"key":"1693_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/jbmr.4188","volume":"36","author":"A Gilsenan","year":"2021","unstructured":"Gilsenan A, Midkiff K, Harris D et al (2021) Teriparatide did not increase adult osteosarcoma incidence in a 15\u2010year US postmarketing surveillance study. J Bone Miner Res 36:244\u2013251. https:\/\/doi.org\/10.1002\/jbmr.4188","journal-title":"J Bone Miner Res"},{"key":"1693_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.01.2010.2681","volume":"2010","author":"A-M Koski","year":"2010","unstructured":"Koski A-M, Siki\u00f6 A, Forslund T (2010) Teriparatide treatment complicated by malignant myeloma. BMJ Case Rep 2010:bcr0120102681. https:\/\/doi.org\/10.1136\/bcr.01.2010.2681","journal-title":"BMJ Case Rep"},{"key":"1693_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4137\/ccrep.s1026","volume":"1","author":"T Forslund","year":"2008","unstructured":"Forslund T, Koski A-M, Koistinen A et al (2008) Malignant myeloma in a patient after treatment for osteoporosis with teriparatide; a rare coincidence. Clin Med Case Rep 1:119\u201322. https:\/\/doi.org\/10.4137\/ccrep.s1026","journal-title":"Clin Med Case Rep"},{"issue":"4","key":"1693_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M et al (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"1693_CR34","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"R Kyle","year":"2010","unstructured":"Kyle R, Durie B, Rajkumar S et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121\u20137. https:\/\/doi.org\/10.1038\/leu.2010.60","journal-title":"Leukemia"},{"issue":"6","key":"1693_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4(6):368\u201381. https:\/\/doi.org\/10.1007\/BF01622200","journal-title":"Osteoporos Int"},{"key":"1693_CR36","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","volume":"359","author":"JA Kanis","year":"2002","unstructured":"Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929\u20131936. https:\/\/doi.org\/10.1016\/S0140-6736(02)08761-5","journal-title":"Lancet"},{"issue":"3","key":"1693_CR37","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM et al (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106(3):812\u20137. https:\/\/doi.org\/10.1182\/blood-2005-03-1038","journal-title":"Blood"},{"key":"1693_CR38","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"1693_CR39","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/ijc.34476","volume":"152","author":"MM Epstein","year":"2023","unstructured":"Epstein MM, Zhou Y, Castaneda-Avila MA et al (2023) Multimorbidity in patients with monoclonal gammopathy of undetermined significance. Int J Cancer 152:2485\u201392. https:\/\/doi.org\/10.1002\/ijc.34476","journal-title":"Int J Cancer"},{"key":"1693_CR40","unstructured":"Facteurs de risque d\u2019ost\u00e9oporose dans une cohorte de 1160 patients porteurs d\u2019une gammapathie monoclonale de signification ind\u00e9termin\u00e9e. Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie. http:\/\/mediatheque.larhumatologie.fr\/mediatheque\/media.aspx?mediaId=232052&channel=5730 (accessed 16 May 2025)"},{"key":"1693_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-210896","volume":"2015","author":"ER Mumford","year":"2015","unstructured":"Mumford ER, Raffles S, Reynolds P (2015) Coexistent osteoporosis and multiple myeloma: when to investigate further in osteoporosis. BMJ Case Rep 2015:bcr2015210896. https:\/\/doi.org\/10.1136\/bcr-2015-210896","journal-title":"BMJ Case Rep"},{"key":"1693_CR42","doi-asserted-by":"publisher","DOI":"10.4274\/tod.galenos.2021.24582","author":"Z Erdemir","year":"2022","unstructured":"Erdemir Z, \u00dcn\u00fcbol A\u0130, \u00dcn\u00fcbol M et al (2022) Multiple myeloma case developed during the use of the teriparatide. Turk J Osteoporos. https:\/\/doi.org\/10.4274\/tod.galenos.2021.24582","journal-title":"Turk J Osteoporos"},{"key":"1693_CR43","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00198-025-07540-y","volume":"36","author":"M Rippl","year":"2025","unstructured":"Rippl M, Grupp P, Martini S et al (2025) Characteristics and treatment options of 272,152 geriatric patients with very high and high fracture risk. Osteoporos Int 36:1257\u201366. https:\/\/doi.org\/10.1007\/s00198-025-07540-y","journal-title":"Osteoporos Int"},{"key":"1693_CR44","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","volume":"116","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY, Tang M, Pfeiffer RM et al (2010) Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood 116:2651\u20135. https:\/\/doi.org\/10.1182\/blood-2010-04-282848","journal-title":"Blood"},{"key":"1693_CR45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(17)32137-2","journal-title":"Lancet"},{"key":"1693_CR46","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","volume":"112","author":"Y-W Qiang","year":"2008","unstructured":"Qiang Y-W, Chen Y, Stephens O et al (2008) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112:196\u2013207. https:\/\/doi.org\/10.1182\/blood-2008-01-132134","journal-title":"Blood"},{"key":"1693_CR47","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1002\/ijc.22033","volume":"119","author":"MC Politou","year":"2006","unstructured":"Politou MC, Heath DJ, Rahemtulla A et al (2006) Serum concentrations of dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 119:1728\u20131731. https:\/\/doi.org\/10.1002\/ijc.22033","journal-title":"Int J Cancer"},{"key":"1693_CR48","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1210\/jc.2010-0720","volume":"95","author":"MT Drake","year":"2010","unstructured":"Drake MT, Srinivasan B, M\u00f6dder UI et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056\u20135062. https:\/\/doi.org\/10.1210\/jc.2010-0720","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01693-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01693-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01693-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T11:42:46Z","timestamp":1774784566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01693-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1693"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01693-x","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RC declares no conflict of interest. CP received honoraries from Eli Lilly, Galapagos, AbbVie, Kyowa Kirin, Fresenius Kabi, and Amgen. BC received honoraries from Alexion, Amgen, Besins, Kyowa-Kirin, Theramex, UCB, and Viatris. JP received honoraries from Amgen, Pfizer, MSD, Theramex, Kyowa Kirin, and Eli Lilly. BB, DT, CAP, and SM declare no conflict of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"59"}}